What is Sven Wehrwein’s total AtriCure (ATRC) share ownership after this grant?

After the 6,144-share grant, Sven Wehrwein directly holds 40,518 AtriCure common shares. This total reflects his position immediately following the reported equity award and helps show the scale of his ongoing ownership stake in the company.

AtriCure (ATRC) director Sven Wehrwein receives 6,144-share restricted stock grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

WEHRWEIN SVEN reported acquisition or exercise transactions in this Form 4 filing.

AtriCure, Inc. director Sven Wehrwein received a grant of 6,144 shares of common stock as equity compensation. The award was made at a price of $0.00 per share under the AtriCure, Inc. 2023 Stock Incentive Plan and is structured as a Restricted Stock Award. According to the terms, these shares will vest on the one-year anniversary of the grant date. Following this grant, Wehrwein directly holds a total of 40,518 shares of AtriCure common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider WEHRWEIN SVEN

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	6,144	$0.00	--

Holdings After Transaction: Common Stock — 40,518 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Restricted stock grant: 6,144 shares Grant price: $0.00 per share Total holdings after grant: 40,518 shares +1 more

4 metrics

Restricted stock grant 6,144 shares Equity award on 2026-05-18

Grant price $0.00 per share Compensation-related stock award

Total holdings after grant 40,518 shares Director’s direct ownership post-transaction

Vesting term One year Shares vest on one-year anniversary of grant date

Key Terms

Restricted Stock Award, AtriCure, Inc. 2023 Stock Incentive Plan, vest

3 terms

Restricted Stock Award financial

"The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan."

A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.

AtriCure, Inc. 2023 Stock Incentive Plan financial

"pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan."

vest financial

"The shares will vest upon the one-year anniversary of the grant date."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Form 4 Insider Transactions: What Each Field Means →

05/20/2026 - 09:25 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WEHRWEIN SVEN

(Last)

(First)

(Middle)

4877 EAST LAKE HARRIET PARKWAY

(Street)

MINNEAPOLIS

MINNESOTA

55419

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/18/2026		A		6,144⁽¹⁾	A	$0	40,518	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

Remarks:

	/s/ Allison Walker as Attorney-in-fact for Sven Wehrwein	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did AtriCure (ATRC) director Sven Wehrwein report in this Form 4?

Sven Wehrwein reported receiving a grant of 6,144 shares of AtriCure common stock. The award was made at $0.00 per share as equity compensation and increased his direct holdings to 40,518 shares after the transaction.

How many AtriCure (ATRC) shares were granted to Sven Wehrwein?

Sven Wehrwein was granted 6,144 shares of AtriCure common stock. These shares were issued as a Restricted Stock Award under the company’s 2023 Stock Incentive Plan and added to his existing equity position in the company.

At what price were the AtriCure (ATRC) shares granted to Sven Wehrwein?

The 6,144 AtriCure shares granted to Sven Wehrwein carried a transaction price of $0.00 per share. This indicates a compensation-related stock award rather than an open-market purchase involving cash paid by the director.

When will Sven Wehrwein’s new AtriCure (ATRC) Restricted Stock Award vest?

The Restricted Stock Award granted to Sven Wehrwein will vest on the one-year anniversary of the grant date. Vesting means the shares become fully owned without forfeiture conditions once that one-year period has passed, assuming applicable conditions are met.

Under which plan was the AtriCure (ATRC) stock granted to Sven Wehrwein?

The grant was made under the AtriCure, Inc. 2023 Stock Incentive Plan as a Restricted Stock Award. This plan is used by the company to deliver equity-based compensation to eligible participants, aligning their interests with long-term shareholder value.